Pharmaceutical
Filter News
Found 56,020 articles
-
Inotiv, Inc. to Present at Jefferies 2023 Healthcare Conference
5/25/2023
Inotiv, Inc. announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will present at the Jefferies Healthcare Conference, being held in New York, NY, from June 7-9, 2023.
-
Clene Awarded Grant From National Multiple Sclerosis Society to Advance Development of CNM-Au8® in Non-Active Progressive Multiple Sclerosis
5/25/2023
Clene, Inc., along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc. announced that Clene has received a grant from the National Multiple Sclerosis Society via the organization’s Fast Forward Program, a competitive, expert-reviewed funding opportunity to support commercial organizations that are developing new therapies for the treatment of multiple sclerosis.
-
Teknova to Participate in Upcoming June 2023 Investor Conference
5/25/2023
Alpha Teknova, Inc. announced that the Company will present and host individual and small group meetings at the following upcoming investor conference:
-
Achieve Life Sciences Announces Pricing of $16.5 Million Registered Direct Offering
5/25/2023
Achieve Life Sciences, Inc. announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase and sale of 3,000,000 shares of common stock at a price of $5.50 per share in a registered direct offering.
-
Indivior To Participate In Upcoming June 2023 Investor Conferences
5/25/2023
Indivior PLC announced that it will participate in the following investor events:
-
Propanc Biopharma’s Intellectual Property Portfolio Makes Important Advancements in Europe
5/25/2023
Propanc Biopharma, Inc., a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced that the Company’s intellectual property portfolio made important advancements in Europe.
-
Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
5/25/2023
The Combined General Shareholders’ Meeting of Sanofi was held on May 25, 2023, under the chairmanship of Serge Weinberg.
-
ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis
5/25/2023
ZyVersa Therapeutics, Inc. announces publication of an article in the peer-reviewed journal, Frontiers in Medicine, demonstrating a role for innate inflammasome activation in two of the most common types of JIA, oligo- and poly-articular, both of which are typically thought to be classical antigen-driven autoimmune conditions.
-
HARMONY BIOSCIENCES COMPLETES ENROLLMENT OF PHASE 3 REGISTRATIONAL INTUNE STUDY IN IDIOPATHIC HYPERSOMNIA
5/25/2023
Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY) today announced that its Phase 3 registrational INTUNE study evaluating the safety and efficacy of pitolisant in adult patients with idiopathic hypersomnia (IH) has completed enrollment nine months before its estimated enrollment completion date.
-
Pharming Group to attend the following Investor Conferences in June 2023
5/25/2023
Pharming Group N.V. announces that Pharming's management will attend the following investor conferences in the month of June.
-
Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting
5/25/2023
Deciphera Pharmaceuticals, Inc. announced four poster presentations at the upcoming 2023 American Society of Clinical Oncology Annual Meeting, being held in Chicago, Illinois on June 2-6, 2023.
-
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
5/25/2023
RAPT Therapeutics, Inc. announced biomarker data for FLX475 from its ongoing FLX475-02 Phase 1/2 clinical trial which corroborate the clinical activity of FLX475 reported in Epstein-Barr virus-positive lymphoma, EBV+ gastric cancer and non-small cell lung cancer, as well as the mechanism of this novel CCR4 antagonist.
-
Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives
5/25/2023
Reviva Pharmaceuticals Holdings, Inc. has presented preclinical data on the novel serotonin-dopamine modulator brilaroxazine in idiopathic pulmonary fibrosis at the 2023 American Thoracic Society International Conference which took place in Washington, DC, USA, May 19-24, 2023.
-
Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
5/25/2023
Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced updated data from Part A of the ongoing registration-directed RAMP 201 trial evaluating the safety and efficacy of avutometinib alone and in combination with defactinib among patients with recurrent low-grade serous ovarian cancer.
-
Servier Targets Transformative Treatment of Cancer at ASCO 2023
5/25/2023
Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will showcase new data across its robust oncology portfolio at the American Society of Clinical Oncology annual meeting June 2-6, 2023.
-
Pipeline Therapeutics to Present at the 2023 Jefferies Global Healthcare Conference
5/25/2023
Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced that Carmine Stengone, CEO of Pipeline, will present on June 9, 2023 at 12:15pm ET at the 2023 Jefferies Global Healthcare Conference, being held June 7-9, 2023 in New York, NY.
-
Landos Biopharma Announces 1-for-10 Reverse Stock Split
5/25/2023
Landos Biopharma, Inc. announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10, to be effective as of 5:00 p.m. Eastern Time today, May 25, 2023.
-
Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value
5/25/2023
Alkermes plc filed its definitive proxy statement with the U.S. Securities and Exchange Commission and issued a letter to its shareholders in connection with the Company's upcoming 2023 Annual General Meeting of Shareholders, which is scheduled to be held on June 29, 2023.
-
Pfizer Presents Scientific Advancements from its Leading Oncology Portfolio at ASCO 2023 Annual Meeting
5/25/2023
Pfizer Inc. will present data across its Oncology portfolio and growing pipeline, covering multiple tumor types and novel mechanisms of action at the 2023 American Society of Clinical Oncology Annual Meeting in Chicago from June 2 through June 6.
-
Vigeo Therapeutics New Immune Profiling and Biomarker Data Ph I/II Expansion study in GBM Patients
5/25/2023
Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, announced encouraging new data from its phase I/II expansion study evaluating single-agent activity of VT1021 in patients with recurrent glioblastoma.